|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03737 ZHONGZHIPHARM
Nominal 
0.980 +0.010 (+1.031%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 2,049,812 | 12.261% | 1,825,935 | 1,746,500 | 1,603,876 | 1,342,182 |
| Cost of Sales | (831,669) | 10.354% | (753,640) | (685,061) | (612,673) | (507,493) |
| Gross Profit | 1,218,143 | 13.601% | 1,072,295 | 1,061,439 | 991,203 | 834,689 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 207,581 | 58.882% | 130,651 | 61,813 | 167,222 | 155,941 | |
| Taxation | (43,447) | 83.043% | (23,736) | (9,447) | (28,603) | (41,247) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (1,359) | 157.386% | (528) | (238) | (87) | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 162,775 | 53.003% | 106,387 | 52,128 | 138,532 | 114,694 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 883 | -66.892% | 2,667 | 2,938 | (4,802) | (4,193) |
| Depreciation & Amortisation | 102,079 | 5.909% | 96,384 | 85,052 | 99,749 | 63,534 |
| Directors' Emoluments | 6,586 | 8.144% | 6,090 | 5,377 | 5,451 | 5,354 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified (Modified Report) | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 19.000 | 46.154% | 13.000 | 6.000 | 17.000 | 14.000 |
| DPS (cts) | 8.170 | -- | 7.880 | 0.000 | 4.328 | 8.159 |
| Dividend Payout Ratio (%) | 43.000% | -- | 60.612% | -- | 25.457% | 58.282% |
| Cash flow per share ($) | 0.120 | -- | 0.336 | 0.213 | 0.112 | 0.201 |
| NBV per share ($) | 1.214 | -- | 1.161 | 1.041 | 0.976 | 0.909 |
| Remarks: | Real time quote last updated: 28/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 83,440 |
| %Change | -38.147% |
| EPS / (LPS) | RMB 0.099 |
| NBV Per Share (¥) | RMB 1.282 |